Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

World Rank (Aug-2026)
5466
Market Cap (Aug-2026)
2.612 Billion USD
Market Cap (Mar-08-2026)
2.053 Billion USD
World Rank (Jan-05-2024)
3,549
Market Cap (Jan-05-2024)
3.941 Billion USD
World Rank (Jul-30-2023)
4,303
Market Cap (Jul-30-2023)
3.053 Billion USD
World Rank (Jan-07-2022)
3,267
Market Cap (Jan-07-2022)
5.030 Billion USD
World Rank (Jan-01-2021)
1,805
Market Cap (Jan-01-2021)
9.158 Billion USD
Headquarters Country
USA
Top Healthcare Companies in USA
Top Pharmaceutical Companies in USA
Nasdaq / NYSE Code
RARE
Employee Count
1,119
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
673 Million USD
Annual Operating Income in USD
-535 Million USD
Annual Net Income in USD
-575 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
1,532 Million USD
Total Liabilities in USD
1,605 Million USD
Total Equity in USD
-80 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Pharmaceutical
Biotechnology
Biopharmaceutical
HealthCare Products
Company Website
ULTRAGENYX PHARMACEUTICAL INC
Yahoo
Yahoo @ Nasdaq
Company Profile

Ultragenyx Pharmaceutical is a Clinical Stage Biopharmaceutical company. It committed to bringing to patients novel products for the treatment of rare and ultra rare diseases with a focus on serious debilitating genetic diseases. The company portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for which there are no approved therapies. The headquarters is in USA.

Annual Results Summary

ULTRAGENYX PHARMACEUTICAL - Annual Results Summary - in Million USD

Year Ending:Total RevenueOperating IncomeNet Income
Dec-2022363-648 (Loss)-707 (Loss)
Dec-2021351 -381 (Loss) -454 (Loss)
Dec-2020271(330) (Loss)(187) (Loss)
Dec-2019104(424) (Loss)(403) (Loss)
Dec-201851.5(371) (Loss)(198) (Loss)
Dec-20172.6(329) (Loss)(302) (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,545 Million USD.

Total Liabilities as on Dec-2022 was 1,192 Million USD.

Total Equity as on Dec-2022 was 352 Million USD

Founded Year
2010
IPO Year
2014
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share